Individualized Holding and Bridging Therapy Achieves High Response Rates and Reduces Toxicity of Bcma-Directed CAR-T Cell Therapy in Multiple Myeloma (IMS 2026) - Sep 11, 2026 - Abstract #PA-254; Pres time: Sep 24, 2026; " In this single-center retrospective analysis, 88 consecutive RRMM patients received idecabtagene vicleucel (ide-cel; n=22) or ciltacabtagene autoleucel (cilta-cel; n=66). Adaptive, individualized holding and bridging therapy with a wide variety of treatment regimens achieved high pre-infusion response rates. Intensive chemotherapy as holding therapy did not compromise CAR-T product quality or manufacturing success. Deeper pre-infusion disease control was associated with significantly lower composite toxicity after BCMA-directed CAR-T therapy without severe neurotoxicity, positioning pre-infusion response as a potentially modifiable determinant of CAR-T-related toxicity."
CAR T-Cell Therapy • Clinical • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Multiple Myeloma • Rare Diseases
|
|
Jule Artzenroth1; Ricardo Kosch1; Leandra Bartke1; Leon Cords1; Maximilian Al-Bazaz1; Corinna Güsmer1; Marie Harzer1; Abdulaziz Kamili1; Lisa B. Leypoldt1; Ramin Madanchi1; Malte Benedikt Monin1; Christoph Schaefers1; Theresa Schlemmer1; Johan Seibel1; Carsten Bokemeyer1; Katja Weisel1; Winfried Alsdorf1
|